BIOMAT Database Logo BIOMAT Database Logo

Immunologic mechanism in sulphasalazine-induced agranulocytosis. 1990

R M Victorino, and V A Maria, and J de Deus

UI MeSH Term Description Entries
D004342 Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally. Allergy, Drug,Hypersensitivity, Drug,Drug Allergy,Allergies, Drug,Drug Allergies,Drug Hypersensitivities,Hypersensitivities, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000380 Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS). Granulocytopenia,Agranulocytoses,Granulocytopenias
D012460 Sulfasalazine A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) Salicylazosulfapyridine,Asulfidine,Azulfadine,Azulfidine,Azulfidine EN,Colo-Pleon,Pleon,Pyralin EN,Salazopyrin,Salazosulfapyridine,Sulfasalazin medac,Sulfasalazin-Heyl,Sulfasalazine FNA,Sulphasalazine,Ucine,Ulcol,ratio-Sulfasalazine,Colo Pleon,Sulfasalazin Heyl,ratio Sulfasalazine

Related Publications

R M Victorino, and V A Maria, and J de Deus
Sulphasalazine induced agranulocytosis.
July 1983, The New Zealand medical journal,
R M Victorino, and V A Maria, and J de Deus
Sulphasalazine induced agranulocytosis revisited.
December 1998, Irish medical journal,
R M Victorino, and V A Maria, and J de Deus
Aprindine-induced agranulocytosis. Evidence for immunologic mechanism.
February 1983, Archives of internal medicine,
R M Victorino, and V A Maria, and J de Deus
Sulphasalazine-induced agranulocytosis successfully treated with filgrastim.
April 1996, Australian and New Zealand journal of medicine,
R M Victorino, and V A Maria, and J de Deus
Sulphasalazine induced agranulocytosis in a patient with rheumatoid arthritis.
June 1990, Irish journal of medical science,
R M Victorino, and V A Maria, and J de Deus
Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis.
February 2000, Pharmacogenetics,
R M Victorino, and V A Maria, and J de Deus
Agranulocytosis associated with sulphasalazine therapy.
September 1973, Postgraduate medical journal,
R M Victorino, and V A Maria, and J de Deus
Immunologic agranulocytosis?
January 1953, Acta medica Scandinavica,
R M Victorino, and V A Maria, and J de Deus
Agranulocytosis associated with sulphasalazine ('Salazopyrin') therapy.
June 1963, Lancet (London, England),
R M Victorino, and V A Maria, and J de Deus
Treatment of sulphasalazine-induced agranulocytosis with granulocyte macrophage-colony stimulating factor.
December 1995, Alimentary pharmacology & therapeutics,
Copied contents to your clipboard!